However, some patients with low or negative tumor PD-L1 expression respond well to ICI therapy, possibly due to intratumoral heterogeneity, the site of the tumor biopsy, temporal fluctuations in PD-L1 after prior therapy, and/or other factors. The gene discussed is CD274; the disease is neoplasm.